Background: Alzheimer disease (AD) typically affects behavior, memory and thinking. The
change in brain have been reported to begin approx. 10-20 years before the appearance of actual symptoms
and diagnosis of AD. An early stage diagnosis and treatment of this lethal disease is the prime
challenge, which is mainly halted by the lack of validated biomarkers.
Method: Recent nanotechnological advancements have the potential to offer large scale effective diagnostic
and therapeutic options. Targeted drug (e.g. Rivastigmine) delivery with the help of nanoparticles
(NPs) in the range of 1-100 nm diameters can effectively cross the blood brain barrier with minimized
side effects. Moreover, biocompatible nanomaterials with increased magnetic and optical properties can
act as excellent alternative agents for an early diagnosis. With the high volume of research coming in
support of the effective usage of NP based drug delivery in critical environment of CNS, it is quite likely
that this approach can end up providing remarkable breakthroughs in early stage diagnosis and therapy
Conclusion: In the current review, we have presented a comprehensive outlook on the current challenges
in diagnosis and therapy of AD, with an emphasis on the effective options provided by biocompatible
NPs as imaging contrast agents and drug carriers.